-54%

est. 2Y upside i

HealthcareSeries B

Plenful is a healthcare AI-powered workflow automation platform for pharmacy and healthcare operations, streamlining manual and administrative tasks to reduce costs and drive revenue. Trusted by leading pharmacy and healthcare teams, Plenful provides highly configurable automation solutions for 340B auditing and savings identification, document data entry, inventory management, and other high ROI use-cases.

Rank

#842

Sector

Healthcare AI & Automation

Est. Liquidity

~4Y

Data Quality

Data: Medium

Plenful presents a strong upside opportunity for a job seeker, driven by its specialized AI platform addressing a massive, underserved healthcare automation market.

Last updated: March 10, 2026

Bull (20%)+300%

Plenful rapidly expands its AI platform beyond pharmacy into broader healthcare operations, achieving $60M+ ARR by early 2028. This market leadership and strong execution lead to a strategic acquisition or a successful Series C round at a a $1B+ valuation, representing a 4x return on current valuation, capped at 300% for Series B stage.

Base (50%)+100%

Plenful continues to grow steadily within its core pharmacy and 340B automation niche, reaching ~$35M ARR by early 2028. The company secures further funding or is acquired at a $500M+ valuation, providing a 2x return on current equity.

Bear (30%)-50%

Increased competition from incumbents like Microsoft Power Automate or Epic, or slower-than-expected market adoption, limits Plenful's growth to ~$22M ARR by early 2028. A challenging funding environment leads to a down round at a $125M valuation, severely impacting common stock value due to existing liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Investors hold $76M in liquidation preferences ahead of common stock, representing 30.4% of the estimated current valuation of $250M.

Dilution Risk

high

As a Series B company, Plenful will likely require at least one to two more significant funding rounds before a liquidity event, leading to further dilution for common shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Plenful's shares at this stage.

Other — 1 role

View all 1 open roles at Plenful →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Plenful's data — designed to show you've done your homework.

  • 1

    “Given the significant market presence of established healthcare IT vendors like Epic and Cerner, how does Plenful plan to integrate or differentiate its specialized AI automation platform to avoid direct competition and capture market share effectively?”

  • 2

    “With ~$14M in revenue and a recent Series B, what are the key metrics and growth levers the company is prioritizing over the next 12-18 months to achieve its next funding milestone or profitability?”

  • 3

    “Considering the Series B funding and the typical timeline for venture-backed companies, what is the company's anticipated path and timeline towards a liquidity event for employees, and how is dilution managed across future funding rounds?”

Community

Valuation Sentiment

Our model estimates -54% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.